To the editor
Apoptosis is executed by the effector caspases-3 and -7, which normally reside as latent precursors (zymogens) in most of the nucleated cells of the human body. The physiologic mechanism for their activation requires cleavage, and such cleavage is generated by a proteolytic attack by the apical caspase-8 or caspase-9, or by the caspase analog granzyme B. It therefore came as an exciting surprise when, in a previous issue of Nature Chemical Biology1, Hergenrother and colleagues reported on a series of small molecules that could directly activate the zymogens of caspases-3 and -7, because such compounds could form the basis of new anti-neoplastic therapeutics. In the normal process, proteolysis of caspase zymogens results in a gain of activity of several orders of magnitude2. Hence, we were surprised that Putt and co-workers could only obtain a 3–4.5-fold relative increase in activity (as monitored by UV), especially since the authors observed >50% cleavage of procaspase-3 within 4 h by western blotting; this apparent discrepancy prompted us to examine the utility of PAC-1.
We obtained PAC-1, and several analogs that included both active (PAC-2; compound 2 in ref. 1) and inactive compounds (PAC-3; compound 3 in ref. 1), from ChemDiv and ChemBridge (the same vendor that supplied PAC-1 for the initial screen described in Putt et al.1). We fully characterized these compounds by LC-MS and NMR, confirming the structure and purity at >99%. In two independent laboratories, we conducted several types of assays, all of which represent well-established systems to measure and detect executioner caspase activation.(i) In assays similar to those described by Putt and co-workers, we tested each compound in both chromogenic (Ac-DEVD-pNA) and fluorogenic (Ac-DEVD-AMC) assays for their potency in activating purified recombinant procaspase-3 and procaspase-7 expressed in Escherichia coli (Fig. 1a). (ii) We treated procaspase-3 and -7 for 14 h with the panel of PAC molecules and analyzed the proteins for cleavage by gel electrophoresis (Fig. 1b). (iii) We used extracts from cell lines to determine whether the compounds could activate endogenous caspases in this frequently used model of cell-free apoptosis3,4 (Fig. 1c). In all of these assays and others not described here, we did not detect any reproducible caspase activation or proteolytic processing over background levels. In contrast, the canonical activator granzyme B rapidly generated massive activation and complete processing of the caspase zymogens (Fig. 1b,c).
In addition, the authors suggested that MCF7 cells, which do not express procaspase-3, are resistant to PAC-1, supporting the hypothesis that PAC-1 exerts its activity by directly activating caspase-3 (ref. 1). We tested the effect of PAC-1 on MCF7 cells, but found that PAC-1 was able to kill these cells with an efficacy similar to that obtained with H226 and SK-MEL-5 cells (which contain substantial procaspase-3), arguing against a direct caspase-activating mechanism for the compound. In sum, we suggest that PAC-1 and related compounds do not activate executioner caspases by a direct mechanism, and we look forward to a further explanation of this compound's mode of action.
References
Putt, K.S. et al. Nat. Chem. Biol. 2, 543–550 (2006).
Zhou, Q. & Salvesen, G.S. Biochem. J. 324, 361–364 (1997).
Li, P. et al. Cell 91, 479–489 (1997).
Ellerby, H.M. et al. J. Neurosci. 17, 6165–6178 (1997).
Stennicke, H.R. & Salvesen, G.S. Methods 17, 313–319 (1999).
Author information
Authors and Affiliations
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Denault, JB., Drag, M., Salvesen, G. et al. Small molecules not direct activators of caspases. Nat Chem Biol 3, 519 (2007). https://doi.org/10.1038/nchembio0907-519
Issue Date:
DOI: https://doi.org/10.1038/nchembio0907-519
This article is cited by
-
Procaspase-3-activating compound 1 stabilizes hypoxia-inducible factor 1α and induces DNA damage by sequestering ferrous iron
Cell Death & Disease (2018)
-
A novel caspase 8 selective small molecule potentiates TRAIL-induced cell death
Scientific Reports (2015)
-
Essential requirement of cytochrome c release for caspase activation by procaspase-activating compound defined by cellular models
Cell Death & Disease (2011)